Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients A GEICO study

International Journal of Gynecological Cancer

Volumn 21, Issue 6, 2011, Pages 1048-1055

  Oaknin, Ana ^a   Roda, Desamparado ^b   González Martín, Antonio ^c   Chiva, Luis ^c   García Donas, Jesús ^d   De Juan, Ana ^e   Redondo, Andrés ^f   Martínez, Sergio ^g   García, Yolanda ^h   Catot, Sílvia ⁱ   Ponce, Jordi ^j   Del Campo, J M ^a   Cervantes, Andrés ^b   Poveda, Andrés ^k  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h Servicio de Oncología Médica   (Spain)

ⁱ Althaia   (Spain)

^j HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^k Oncogynecologic Area   (Spain)

more..

Author keywords

Cisplatin; Modified chemotherapy regimen; Ovarian cancer; Paclitaxel

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL PRACTICE; CONSTIPATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; NAUSEA; NEUTROPENIA; OUTPATIENT CARE; OVARY CANCER; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OUTPATIENTS; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 83055178967     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821ee777     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225Y249.
2. du Bois A, Quinn M, Thigpen T, et al. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16:viii7Yviii12. (Pubitemid 41631227)
3. Fujiwara K, Armstrong D, Morgan M, et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17:1Y20. (Pubitemid 46213964)
4. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1Y9.
5. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1986;97:845Y851.
6. Markman M. Intraperitoneal chemotherapy. Semin Oncol. 1991;18:248Y254.
7. Los G, Verdegaal EM, Mutsaers PH, et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159Y165.
8. Kirmani S, Braly PS, McClay EF, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol. 1994;54:338Y344. (Pubitemid 24301910)
9. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950Y1955. (Pubitemid 26428219)
10. Polyzos A, Tsavaris N, Kosmas C, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology. 1999;56:291Y296. (Pubitemid 29240353)
11. Gadducci A, Carnino F, Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol. 2000;76:157Y162. (Pubitemid 30067189)
12. Yen MS, Juang CM, Lai CR, et al. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet. 2001;72:55Y60.
13. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001Y1007. (Pubitemid 32176274)
14. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34Y43. (Pubitemid 43048949)
15. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100:27Y32. (Pubitemid 41815045)
16. National Cancer Institute. NCI clinical announcement. Intraperitoneal chemotherapy for ovarian cancer. Available at: . Accessed March 10, 2010.
17. Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol. 2006;28:4528Y4530. (Pubitemid 46630945)
18. Walker JL. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol. 2009;112:439Y440.
19. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1Y6. (Pubitemid 26012496)
20. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654Y2666. (Pubitemid 24379653)
21. Berry E, Matthews KS, Singh DK, et al. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol. 2009;113:63Y67.
22. Guardiola E, Delroeux D, Heyd B, et al. Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol. 2009;7:14.
23. Seamon LG, Carlson MJ, Richardson DL, et al. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer. 2009;19:1195Y1198.
24. Lesnock JL, Richard SD, Zorn KK, et al. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecol Oncol. 2010;116:345Y350.
25. Gray HJ, Shah CA, Swensen RE, et al. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecol Oncol. 2010;116:340Y344.
26. Chin SN, Pinto V, Rosen B, et al. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Gynecol Oncol. 2009;112:450Y454.
27. Markman M. Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin. Ther Clin Risk Manag. 2009;5:161Y168.